Loading stock data…
Bio-Rad Laboratories (BIO)
$294.42-6.37 (-2.12%)
Market OpenUpdated 3:16 PM EDT
Bio-Rad Laboratories, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bio-Rad Laboratories, Inc. in the Healthcare sector is trading at $294.42 with a market capitalization of $7.8B. Wall Street consensus targets $297.00 (5 analysts), implying a +0.9% move over the next 12 months. The stock is currently 14% below its 52-week high of $343.12, remaining 0.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $592.10M↓ | $693.20M↑ | $653.00M↑ | $651.60M↑ | $585.40M |
| Gross Profit | $309.40M↓ | $345.20M↑ | $343.40M↓ | $345.30M↑ | $306.00M |
| Operating Income | $34.10M↓ | $53.90M↓ | $63.90M↓ | $77.10M↑ | $23.70M |
| Net Income | -$527.10M↓ | $720.00M↑ | -$341.90M↓ | $317.80M↑ | $64.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.84B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.46%
Volume
Today's trading volume
128,835
Recent News
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.
Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?
On May 18, 2026, Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and began pressing for changes to improve shareholder outcomes, focusing in part on the company’s large holding in Sartorius, valued at about US$5.00 billion. An interesting angle is that the market now values Bio-Rad’s Sartorius stake at nearly the company’s entire market value, raising questions about how much credit investors are giving to Bio-Rad’s core operating business. With Elliott’s...
Elliott Targets Bio-Rad After 70% Stock Collapse
Elliott reportedly built a sizable Bio-Rad stake as the life-science tools supplier trades far below its late-2021 peak.
Stocks Settle Mixed as Iran War Remains Unresolved
The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.45%. June E-mini S&P futures (ESM26 ) fell -0.12%, and June E-mini Nasdaq futures...
Stocks Pressured by a Rebound in Crude Prices and Bond Yields
The S&P 500 Index ($SPX ) (SPY ) today is down -0.20%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%. June E-mini S&P futures (ESM26 ) are down -0.28%, and June E-mini Nasdaq futures...